Remicade® (infliximab): 20 years of contributions to science and medicine
Richard Melsheimer,1 Anja Geldhof,1 Isabel Apaolaza,1 Thomas Schaible21Medical Affairs, Janssen Biologics BV, Leiden, the Netherlands; 2Medical Affairs, Janssen Pharmaceuticals, Horsham, PA, USAAbstract: On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/39743cf03df04a5983b7e4012f9b7747 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:39743cf03df04a5983b7e4012f9b7747 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:39743cf03df04a5983b7e4012f9b77472021-12-02T03:05:09ZRemicade® (infliximab): 20 years of contributions to science and medicine1177-5491https://doaj.org/article/39743cf03df04a5983b7e4012f9b77472019-07-01T00:00:00Zhttps://www.dovepress.com/remicadereg-infliximab-20-years-of-contributions-to-science-and-medici-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Richard Melsheimer,1 Anja Geldhof,1 Isabel Apaolaza,1 Thomas Schaible21Medical Affairs, Janssen Biologics BV, Leiden, the Netherlands; 2Medical Affairs, Janssen Pharmaceuticals, Horsham, PA, USAAbstract: On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn’s disease. Subsequently, Remicade was approved in another five adult and two pediatric indications both in the USA and across the globe. In the 20 years since this first approval, Remicade has made several important contributions to the advancement of science and medicine: 1) clinical trials with Remicade established the proof of concept that targeted therapy can be effective in immune-mediated inflammatory diseases; 2) as the first monoclonal antibody approved for use in a chronic condition, Remicade helped in identifying methods of administering large, foreign proteins repeatedly while limiting the body’s immune response to them; 3) the need to establish Remicade’s safety profile required developing new methods and setting new standards for postmarketing safety studies, specifically in the real-world setting, in terms of approach, size, and duration of follow-up; 4) the study of Remicade has improved our understanding of TNF’s role in the immune system, as well as our understanding of the pathophysiology of a range of diseases characterized by chronic inflammation; and 5) Remicade and other TNF inhibitors have transformed treatment practices in these chronic inflammatory diseases: remission has become a realistic goal of therapy and long-term disability resulting from structural damage can be prevented. This paper reviews how, over the course of its development and 20 years of use in clinical practice, Remicade was able to make these contributions.Keywords: Remicade, infliximab, monoclonal antibody, immune-mediated inflammatory disease, TNF inhibition, Crohn’s disease, rheumatoid arthritis Melsheimer RGeldhof AApaolaza ISchaible TDove Medical PressarticleRemicade (infliximab)monoclonal antibodyimmune-mediated inflammatory diseaseTNF inhibitionCrohn’s diseaserheumatoid arthritisMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 13, Pp 139-178 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Remicade (infliximab) monoclonal antibody immune-mediated inflammatory disease TNF inhibition Crohn’s disease rheumatoid arthritis Medicine (General) R5-920 |
| spellingShingle |
Remicade (infliximab) monoclonal antibody immune-mediated inflammatory disease TNF inhibition Crohn’s disease rheumatoid arthritis Medicine (General) R5-920 Melsheimer R Geldhof A Apaolaza I Schaible T Remicade® (infliximab): 20 years of contributions to science and medicine |
| description |
Richard Melsheimer,1 Anja Geldhof,1 Isabel Apaolaza,1 Thomas Schaible21Medical Affairs, Janssen Biologics BV, Leiden, the Netherlands; 2Medical Affairs, Janssen Pharmaceuticals, Horsham, PA, USAAbstract: On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn’s disease. Subsequently, Remicade was approved in another five adult and two pediatric indications both in the USA and across the globe. In the 20 years since this first approval, Remicade has made several important contributions to the advancement of science and medicine: 1) clinical trials with Remicade established the proof of concept that targeted therapy can be effective in immune-mediated inflammatory diseases; 2) as the first monoclonal antibody approved for use in a chronic condition, Remicade helped in identifying methods of administering large, foreign proteins repeatedly while limiting the body’s immune response to them; 3) the need to establish Remicade’s safety profile required developing new methods and setting new standards for postmarketing safety studies, specifically in the real-world setting, in terms of approach, size, and duration of follow-up; 4) the study of Remicade has improved our understanding of TNF’s role in the immune system, as well as our understanding of the pathophysiology of a range of diseases characterized by chronic inflammation; and 5) Remicade and other TNF inhibitors have transformed treatment practices in these chronic inflammatory diseases: remission has become a realistic goal of therapy and long-term disability resulting from structural damage can be prevented. This paper reviews how, over the course of its development and 20 years of use in clinical practice, Remicade was able to make these contributions.Keywords: Remicade, infliximab, monoclonal antibody, immune-mediated inflammatory disease, TNF inhibition, Crohn’s disease, rheumatoid arthritis |
| format |
article |
| author |
Melsheimer R Geldhof A Apaolaza I Schaible T |
| author_facet |
Melsheimer R Geldhof A Apaolaza I Schaible T |
| author_sort |
Melsheimer R |
| title |
Remicade® (infliximab): 20 years of contributions to science and medicine |
| title_short |
Remicade® (infliximab): 20 years of contributions to science and medicine |
| title_full |
Remicade® (infliximab): 20 years of contributions to science and medicine |
| title_fullStr |
Remicade® (infliximab): 20 years of contributions to science and medicine |
| title_full_unstemmed |
Remicade® (infliximab): 20 years of contributions to science and medicine |
| title_sort |
remicade® (infliximab): 20 years of contributions to science and medicine |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/39743cf03df04a5983b7e4012f9b7747 |
| work_keys_str_mv |
AT melsheimerr remicaderegnbspinfliximabnbsp20yearsofcontributionstoscienceandmedicine AT geldhofa remicaderegnbspinfliximabnbsp20yearsofcontributionstoscienceandmedicine AT apaolazai remicaderegnbspinfliximabnbsp20yearsofcontributionstoscienceandmedicine AT schaiblet remicaderegnbspinfliximabnbsp20yearsofcontributionstoscienceandmedicine |
| _version_ |
1718401977058066432 |